Recent development of multi-targeted inhibitors of human topoisomerase II enzyme as potent cancer therapeutics

被引：15

作者：

Singh, Vishal ^{[1
]}

Afshan, Tayyaba ^{[1
]}

Tyagi, Pankaj ^{[1
]}

Varadwaj, Pritish Kumar ^{[1
]}

Sahoo, Amaresh Kumar ^{[1
]}

机构：

[1] Indian Inst Informat Technol Allahabad, Dept Appl Sci, Allahabad 211015, Uttar Pradesh, India

来源：

INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES | 2023年 / 226卷

关键词：

Topoisomerase II; Drug resistance; Apoptosis; Multi -targeted inhibitors; RECEPTOR TYROSINE KINASES; ALPHA GENE-EXPRESSION; MULTIDRUG-RESISTANCE; CATALYTIC INHIBITOR; DUAL INHIBITOR; HUMAN-CELLS; INTOPLICINE RP-60475; DNA TOPOISOMERASES; DRUG DISCOVERY; PROTEIN-KINASE;

D O I：

10.1016/j.ijbiomac.2022.12.013

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Multi-target therapies have been considered one of the viable options to overcome the challenges to eradicate intrinsic and acquired drug-resistant cancer cells. While to increase the efficacy of therapeutics, the use of a single drug against multiple structurally similar sites, which noncommittedly modulate several vital cellular pathways proposed as a potential alternative to a 'single drug single target'. Besides, it reduces the usage of a number of drugs and their side effects. Topoisomerase II enzyme plays a very significant role in DNA replication and thus served as an important target for numerous anti-cancer agents. However, in spite of promising clinical results, in several cases, it was found that cancer cells have developed resistance against the anti-cancer agents targeting this enzyme. Therefore, multi-target therapies have been proposed as an alternative to overcome different drug resistance mechanisms while topoisomerases II are a primary target site. In this review, we have tried to discuss the characteristics of the binding cavity available for interactions of drugs, and potent inhibitors concurrently modulate the functions of topoisomerases II as well as other structurally related target sites. Additionally, the mechanism of drug resistance by considering molecular and cellular insights by including various types of cancers.

引用

页码：473 / 484

页数：12

共 123 条

[1] Gemcitabine plus paclitaxel versus paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment [J].

Albain, Kathy S. ;

Nag, Shona M. ;

Calderillo-Ruiz, German ;

Jordaan, Johann P. ;

Llombart, Antonio C. ;

Pluzanska, Anna ;

Rolski, Janusz ;

Melemed, Allen S. ;

Reyes-Vidal, Jose M. ;

Sekhon, Jagdev S. ;

Simms, Lorinda ;

O'Shaughnessy, Joyce .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (24) :3950-3957

[2] Polypharmacology: Challenges and Opportunities in Drug Discovery [J].

Anighoro, Andrew ;

Bajorath, Juergen ;

Rastelli, Giulio .

JOURNAL OF MEDICINAL CHEMISTRY, 2014, 57 (19) :7874-7887

[3] Polypharmacology in Precision Oncology: Current Applications and Future Prospects [J].

Antolin, Albert A. ;

Workman, Paul ;

Mestres, Jordi ;

Al-Lazikani, Bissan .

CURRENT PHARMACEUTICAL DESIGN, 2016, 22 (46) :6935-6945

[4] Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies [J].

Azarova, Anna M. ;

Lyu, Yi Lisa ;

Lin, Chao-Po ;

Tsai, Yuan-Chin ;

Lau, Johnson Yiu-Nam ;

Wang, James C. ;

Liu, Leroy F. .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (26) :11014-11019

[5] Contemporary Challenges in the Design of Topoisomerase II Inhibitors for Cancer Chemotherapy [J].

Bailly, Christian .

CHEMICAL REVIEWS, 2012, 112 (07) :3611-3640

[6] The chemokine SDF-1/CXCL12 binds to and signals through the orphan receptor RDC1 in T lymphocytes [J].

Balabanian, K ;

Lagane, B ;

Infantino, S ;

Chow, KYC ;

Harriague, J ;

Moepps, B ;

Arenzana-Seisdedos, F ;

Thelen, M ;

Bachelerie, F .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (42) :35760-35766

[7] Bioflavonoids as poisons of human topoisomerase IIα and IIβ [J].

Bandele, Omari J. ;

Osheroff, Neil .

BIOCHEMISTRY, 2007, 46 (20) :6097-6108

[8] Type IIA topoisomerase inhibition by a new class of antibacterial agents [J].

Bax, Benjamin D. ;

Chan, Pan F. ;

Eggleston, Drake S. ;

Fosberry, Andrew ;

Gentry, Daniel R. ;

Gorrec, Fabrice ;

Giordano, Ilaria ;

Hann, Michael M. ;

Hennessy, Alan ;

Hibbs, Martin ;

Huang, Jianzhong ;

Jones, Emma ;

Jones, Jo ;

Brown, Kristin Koretke ;

Lewis, Ceri J. ;

May, Earl W. ;

Saunders, Martin R. ;

Singh, Onkar ;

Spitzfaden, Claus E. ;

Shen, Carol ;

Shillings, Anthony ;

Theobald, Andrew J. ;

Wohlkonig, Alexandre ;

Pearson, Neil D. ;

Gwynn, Michael N. .

NATURE, 2010, 466 (7309) :935-U51

[9] Tumor cell resistance to DNA topoisomerase II inhibitors: new developments [J].

Beck, WT ;

Morgan, SE ;

Mo, YY ;

Bhat, UG .

DRUG RESISTANCE UPDATES, 1999, 2 (06) :382-389

[10] Recent developments in DNA topoisomerase II structure and mechanism [J].

Berger, JM ;

Wang, JC .

CURRENT OPINION IN STRUCTURAL BIOLOGY, 1996, 6 (01) :84-90

← 1 2 3 4 5 6 7 8 9 10 →